Loading clinical trials...
Loading clinical trials...
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225
Conditions
Interventions
Pembrolizumab
Y90 radioembolization
Locations
3
United States
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
University of Washington/Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Start Date
March 28, 2017
Primary Completion Date
May 19, 2021
Completion Date
June 1, 2023
Last Updated
February 6, 2023
NCT06345508
NCT07485114
NCT06066138
NCT06811116
NCT04380545
NCT07291076
Lead Sponsor
Ashwin Somasundaram
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions